Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive  by Portman, David J. et al.
Contraception 89 (2014) 299–306Original research article
Efficacy and safety of an ascending-dose, extended-regimen
levonorgestrel/ethinyl estradiol combined oral
contraceptive☆,☆☆,☆☆☆,☆☆☆☆,★,★★,★★★
David J. Portmana,⁎, Andrew M. Kaunitzb, Brandon Howardc, Herman Weissd,
Jennifer Hsiehe, Nancy Ricciotti f
aColumbus Center for Women's Health Research, Columbus, OH, USA
bUniversity of Florida College of Medicine–Jacksonville, Jacksonville, FL, USA
cTeva Global Medical Affairs, Frazer, PA, USA
dTeva Global Medical Affairs, Petach Tikva, Israel
eTeva Branded Pharmaceutical Products, R&D, Inc., West Chester, PA, USA
fTeva Branded Pharmaceutical Products, R&D, Inc., Frazer, PA, USA
Received 26 August 2013; revised 15 January 2014; accepted 18 January 2014Abstract
Objective: To evaluate the efficacy and safety of an ascending-dose, extended-regimen (ADER) combined oral contraceptive consisting of
levonorgestrel (LNG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 42 days, LNG 150 mcg/EE 25 mcg for 21 days, LNG 150 mcg/EE 30 mcg for
21 days and EE 10 mcg for 7 days.
Study Design: This was a multicenter, open-label, phase 3, single-arm study. Sexually active women aged 18–40 years were enrolled and
received ADER for up to 1 year (4 consecutive 91-day cycles). Participants kept diaries to record adherence, bleeding/spotting and other
contraceptive use. Efficacy was measured using the Pearl Index and the life-table method; safety and tolerability were assessed through reported
adverse events (AEs).
Results: A total of 3701 women were enrolled and 2144 completed the study. The Pearl Index was 3.19 [95% confidence interval (CI), 2.49–
4.03], based on 70 pregnancies that occurred after ADER initiation and ≤7 days after the last LNG/EE or EE-only pill in women aged 18–35☆ Funding: This study was sponsored by Teva Branded Pharmaceutical Products, R&D, Inc. Funding to support the preparation of this manuscript was
provided to MedVal Scientific Information Services, LLC, by Teva Women's Health, Inc.
☆☆ This manuscript was prepared according to the International Society for Medical Publication Professionals' “Good Publication Practice for
Communicating Company-Sponsored Medical Research: the GPP2 Guidelines” and the International Committee of Medical Journal Editors' “Uniform
Requirements for Manuscripts Submitted to Biomedical Journals.”
☆☆☆ Financial disclosure/conflicts of interest: Dr. Portman: research grants from Teva, Bayer, Warner Chilcott, Actavis, Merck, Agile, Population Council;
consultant: Teva, Actavis; speakers bureau: Teva, Warner Chilcott. Dr. Kaunitz: consultant for Actavis, Agile, Bayer, Merck, Teva. The University of Florida
receives research support from Agile, Bayer and Teva. Dr. Howard is an employee of Teva Global Medical Affairs, Frazer, PA. Dr. Weiss is an employee of Teva
Global Medical Affairs, Petach Tikva, Israel. Ms. Hsieh is an employee of Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA. Ms. Ricciotti is
an employee of Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA.
☆☆☆☆ Statement of authorship: Concept and design (DJP, NR); acquisition of data (DJP, AMK, NR); analysis and interpretation of data (DJP, AMK, BH,
JH, NR); drafting of the manuscript (DJP, AMK, BH, HW, JH, NR); critical revision of the manuscript for important intellectual content (DJP, AMK, BH, HW,
JH, NR); administrative, technical, or logistic support (BH, NR); and supervision (BH, NR).
★ ClinicalTrials.gov clinical trial identifier: NCT00996580
★★ Previous presentation: Portman DJ, Howard B, Weiss H, Kaunitz AM, Ricciotti N. Multicenter open-label study to evaluate efficacy and safety of an
ascending-dose, extended-regimen ethinyl estradiol/levonorgestrel combination oral contraceptive for preventing pregnancy in women [abstract]. Fertil Steril
2012;98:S196–S197.
★★★ Implications statement: An extended-regimen oral contraceptive consisting of levonorgestrel 150 mcg combined with an ascending dose of ethinyl
estradiol (20 mcg for 42 days, 25 mcg for 21 days, 30 mcg for 21 days) followed by ethinyl estradiol 10 mcg alone for 7 days provided safe and effective
prevention of pregnancy with a favorable bleeding profile.
⁎ Corresponding author. David J. Portman, MD, Director, Columbus Center for Women's Health Research, 99 North Brice Road, Suite 120, Columbus, OH
43213, USA. Tel.: 614 864 7755; fax: 614 864 4928.
E-mail address: dportman@ccwhr.com (D.J. Portman).
0010-7824 © 2014 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.contraception.2014.01.013
Open access under CC BY-NC-ND license.
 
300 D.J. Portman et al. / Contraception 89 (2014) 299–306years, excluding cycles in which another contraceptive method was used. Life-table pregnancy rate was 2.82% (95% CI, 2.23%–3.57%) for
all users aged 18–35 years. Unscheduled bleeding/spotting decreased with increasing EE doses within each cycle and decreased after cycle 1.
No unexpected AEs or changes in laboratory parameters were reported.
Conclusion: This study demonstrated that ADER effectively prevented pregnancy with a favorable safety and tolerability profile.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. Keywords: Contraception; Low dose; Bleeding; Spotting1. Introduction
Extended-regimen (ER) combined oral contraceptives
(COCs) have increased in popularity among many women
due to their desire to avoid monthly bleeding [1]. For some
women, bleeding is an inconvenience that interferes with
quality of life and productivity. In others, bleeding is
associated with adverse health effects, such as premenstrual
syndrome, endometriosis and anemia [2].
Numerous studies in various populations have indicated
that many women are willing to consider menstrual
suppression with ER COCs, citing a preference for 4
scheduled bleeding episodes per year or complete elimina-
tion of scheduled bleeding [1,3–6]. Many women's health
care providers also agree: a survey of 301 female OB/GYN
fellows reported that more than half of respondents had
personally suppressed their menstruation with COCs [7].
ER COCs include 84 days of therapy with combined
estrogen and progestin and 7 days of therapy with placebo or
low-dose ethinyl estradiol (EE) [8–10]. Compared with
traditional 28-day COCs, ER COCs reduce the incidence of
menstrual-related symptoms, offer comparable efficacy and
provide improved convenience for women who wish to
avoid scheduled monthly bleeding [8,11]. However,
unscheduled bleeding with ER COCs can occur during
early COC cycles and may result in discontinuation
[8,10,12,13]. In one study of a 20-mcg EE ER COC, 40%
of patients experienced unscheduled bleeding for 7 days or
more in cycle 1 and 9.6% discontinued due to bleeding and/
or spotting [10]. These data suggest that ER COCs causing
less unscheduled bleeding would be clinically useful.
Findings from multiple studies have demonstrated that
unscheduled bleeding with ER COCs that include 20- or 30-
mcg EE tends to occur between days 43 and 58, usually
around day 49, independent of the type of progestin and
estrogen used in the regimen [8,14,15]. One theoretical
strategy for reducing the incidence of unscheduled bleeding
with ER COCs is to increase the dose of estrogen before the
time in the cycle in which unscheduled bleeding is most
likely to occur. Another proposed strategy is to use a low-
dose estrogen instead of placebo during the usual hormone-
free interval (HFI) to suppress follicular development
[10,16–18]. An ER COC incorporating both strategies may
provide effective prevention of pregnancy with greater
ovarian, hormonal and endometrial suppression and endo-
metrial stabilization than traditional regimens [9,10,19,20].A new 91-day ascending-dose, ER (ADER) COC
combines levonorgestrel (LNG) and EE and was designed
to reduce unscheduled bleeding while minimizing total
estrogen exposure [21]. This regimen was approved by the
United States (US) Food and Drug Administration in March
2013 as Quartette™. In this regimen, EE doses increase
when unscheduled bleeding has been most frequently
reported [8,12,21].
The primary objective of this phase 3, open-label clinical
trial was to evaluate efficacy and safety of ADER taken for 1
year by healthy women seeking contraception.2. Methods
2.1. Study design and population
This was a multicenter, open-label, phase 3, single-arm
trial of ADER administered for up to 1 year (4 consecutive
91-day cycles). Each 91-day cycle included LNG 150 mcg
for 84 days combined with EE 20 mcg for 42 days, EE 25
mcg for 21 days, and EE 30 mcg for 21 days, followed by EE
10 mcg for 7 days [22], a dosing schedule identified in an
earlier clinical study that evaluated bleeding patterns with
three different ascending EE dose ERs [21].
The study was conducted at 98 clinical sites in the US
between October 8, 2009, and September 9, 2011 (Clinical-
Trials.gov identifier: NCT00996580). It was designed and
conducted according to the laws, regulations and adminis-
trative provisions relating to the implementation of Good
Clinical Practice in the conduct of clinical trials on medical
products for human use, as applicable by national and
European legislation and as required by the major regulatory
authorities, and in accordance with the Declaration of
Helsinki and its updates. Institutional review board approval
was obtained by all study sites. Participants gave written
informed consent before entering the study.
Sexually active adult women aged 18 to 40 years who
were at risk for pregnancy and agreed to routinely use the
study COC as the only birth control method were enrolled.
Women were excluded if they had a history or current
evidence of any condition that contraindicated COC use,
such as current smoking in women aged ≥35 years, and
current or recent chronic use of medications that could affect
COC efficacy, or use of drugs that required simultaneous use
of contraceptives. There were no weight or body mass index
(BMI) restrictions.
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The current trial consisted of a 4-week screening period, a
1-year treatment period and a posttreatment period of
approximately 3 weeks (Fig. 1).
After the screening visit, eligible women were enrolled
into the study and instructed to take 1 pill daily at
approximately the same time each day, with no interval
between packs, for a total of 4 consecutive 91-day cycles. All
participants were “Sunday starters” and remained Sunday
starters throughout the duration of the trial.
After initiation of ADER, participants were monitored
during multiple follow-up clinic visits (Fig. 1). Urine
pregnancy tests, assessment of vital signs, review of
concomitant medications and recording of adverse events
(AEs) were performed at all visits. Participants also were
contacted and monitored by telephone at selected time
points.
During the trial, all women completed a paper diary to
record their adherence with ADER, bleeding/spotting and
weekly use of other contraceptives. Adherence was also
assessed by pill counts at scheduled study visits and early
termination visits. Women prematurely discontinuing from
the trial were provided with an alternative contraceptive, if
desired.
2.3. Efficacy assessment
Efficacy was evaluated using Pearl Index (PI) and life-
table analyses based on pregnancies classified as having
occurred while “on drug,” defined as a date of conception
after the initiation of ADER and up to and including 7 days
after the last LNG/EE or EE-only pill. Pregnancy was
determined by a urine and/or serum pregnancy test.
Estimated date of conception and gestational age were
determined by transvaginal or abdominal ultrasound.Visit 0
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Fig. 1. Study design. aResults from tests done at the screening visit had to be revi
criteria. Eligible women were dispensed ADER at the enrollment visit. Women w
initiating ADER. Women who were continuous users initiated ADER on the first S
their withdrawal bleed, if applicable. Continuous users on an extended cycle COC d
middle of any 28- or 35-day period of the extended cycle but could, for example,
Week 1/Day 1 began on the day that the first dose of ADER was taken. bThe final
days) following the last dose of ADER for all women, including those who comple
for any reason. Visit 9 had to be completed by all women who took ADER.2.4. Safety assessment
All women who received at least one dose of study
medication were included in the safety analysis. Safety and
tolerability were primarily assessed through AE reports and
changes in vital signs and laboratory data.
2.5. Cycle control assessment
Participants recorded the incidence of vaginal bleeding or
spotting in their daily diaries. Bleeding was defined as
vaginal blood loss that required the use of sanitary
protection; spotting did not require any form of sanitary
protection [23]. Bleeding or spotting that occurred during
days 85 through 91 was considered scheduled; bleeding or
spotting during days 1 through 84 was considered unsched-
uled. Bleeding patterns were analyzed in women with at least
28 days of ADER exposure per cycle.
2.6. Statistical methods
Sample size determination was based on attaining a
certain level of exposure to the investigational product
rather than power considerations. Determination of
efficacy was based on a minimum exposure of the equi-
valent of 20,000 28-day cycle equivalents, with a mini-
mum of 1670 women completing the four 91-day cycles
of ADER for the evaluation of safety. Data were pooled
across centers.
Two populations were defined for the analyses of safety
and efficacy data: the safety population, which included all
women who received 1 or more doses of ADER, and the
pregnancy intent-to-treat (PITT) population, which included
all enrolled women aged 18–35 years at screening who
completed ≥28 days of treatment (a complete cycle
equivalent).3 Cycle 4
atment Period Post-Treatment
Period
Visit 6
(Week 26)
Visit 7
(Week 39)
Visit 8
Early Withdrawal
Visit (Week 52)
Visit 9
Final Study Visitb
(Week 52 + 21 days)
/ 150/
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ewed by the investigator and be consistent with the inclusion and exclusion
ho were new starts or prior users had to have a spontaneous menses prior to
unday following last day of active hormonal administration and the start of
id not have to complete an entire 91-day cycle. Women could not stop in the
stop at the end of card 1 (28 days) or card 2 (56 days) and then start ADER.
study visit occurred approximately 21 days (acceptable window was 21–28
ted the study and those who were withdrawn or discontinued the study early
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reported as the PI. The PI was defined as the number of
contraceptive failures per 100 woman-years of exposure. The
formula was as follows: (100)×(total number of pregnan-
cies)×(13)/(total number of 28-day cycles). PIs in the PITT
population were calculated for all users, typical users and
compliant users. The typical-user analysis included all
complete 28-day cycles in which no other contraception
was used. Women included in the compliant-user analysis
had an overall adherence of ≥80%. All complete 28-day
cycles in compliant users in which no other contraceptionwas
used, ≥2 consecutive pills were not skipped, and prohibited
medication was not used were considered compliant-use
cycles.
Cumulative pregnancy rates at 52 weeks in all users and in
compliant users were also estimated using the life-table
method. Two-sided 95% confidence intervals (CIs) were
calculated for each PI and cumulative pregnancy estimate.
Bleeding patterns, changes in vital signs and changes in
laboratory values were summarized using descriptive statis-
tics (mean, median, standard deviation, minimum and
maximum values).Screened (n=
Enrolled (n=3
Safety popula
P
(women b
Comp
Discontinued study (n=1453)
Adverse event 466 (13.0%)
Bleeding/spotting-related 167 (4.6%)
Lost to follow-up 480 (13.3%)
Noncompliance with protocol
5 (0.1%)
Pregnancy 68 (1.9%)
Protocol violation 16 (0.4%)
Sponsor requested
Other 29 (0.8%)
Completed (n=2144)
Investigator discretion
Participant requested withdrawal
participant’s withdrawal†
137 (3.8%)
35 (1.0%)
217 (6.0%)
Fig. 2. Participant disposition. *Safety population includes women who took at lea
chronic treatment with a medication prohibited by the protocol, consistent nonadhe
intervention that would have confounded bleeding/spotting data or that made it un3. Results
Of the 4962 women screened, 3701 met the inclusion
criteria and were enrolled (Fig. 2), 3597 were included in the
safety population and 2144 women completed the study. The
most common reasons for discontinuation in the safety
population were lost to follow-up (13.3%) and AEs (13.0%).
Overall, the demographic characteristics of the analysis
populations were comparable (Table 1). In the safety
population, approximately 65% of all treated women were
white, 19% were African American, and 11% were Hispanic.
Mean age was 27.1 years; mean BMI was 27.4 kg/m2. BMI
was ≥30 kg/m2 in 29% (1027/3597).
3.1. Efficacy
Seventy of the 2992 women in the PITT population were
determined pregnant on drug (Table 2). The PI for all users,
including all complete 28-day cycle equivalents in which
women took drug, was 3.00 (95% CI, 2.34–3.79). The
typical-use PI was 3.19 (95% CI, 2.49–4.03), and the
compliant-use PI was 2.59 (95% CI, 1.94–3.37). Both the4962)
701)
tion*(n=3597)
Screen failures (n=1261)
ITT population
etween 18 and 35 years)
(n=2992)
leted (n=1912)
Did not take medication (n=104)
Discontinued study (n=1080)
Adverse event 340 (11.4%)
Bleeding/spotting-related
Lost to follow-up 334 (11.2%)
Noncompliance with protocol
Investigator discretion 3 (0.1%)
Pregnancy 65 (2.2%)
Protocol violation 12 (0.4%)
Sponsor requested 15 (0.5%)
Participant requested withdrawal
participant’s withdrawal†
176 (5.9%)
Other 24 (0.8%)
131 (4.4%)
111 (3.7%)
st one dose of ADER. †Reasons for sponsor-requested withdrawal: need for
rence with IP or diary completion, abnormal physical finding that required an
wise to continue hormonal contraception.
Table 1
Demographics and baseline characteristics in the safety and PITT analysis
populations
Variable Safety population
(N=3597)
PITT population
(N=2992)
Race/ethnicity, n (%)
American Indian or Alaska
native
14 (0.4) 12 (0.4)
Asian 78 (2.2) 70 (2.3)
Black or African American 696 (19.3) 548 (18.3)
Native Hawaiian or other
Pacific Islander
10 (0.3) 10 (0.3)
White 2324 (64.6) 1952 (65.2)
Hispanic or Latina 404 (11.2) 335 (11.2)
Other 71 (2.0) 65 (2.2)
Height (in), mean (SD) 64.6 (2.7) 64.6 (2.7)
Age (y), mean (SD) 27.1 (5.7) 25.9 (4.6)
Weight (lb), mean (SD) 162.5 (43.2) 161.7 (43.3)
BMI (kg/m2), mean (SD) 27.4 (7.0) 27.2 (7.0)
BMI category, n (%)a
b25 kg/m2 1683 (46.8) 1424 (47.6)
25–30 kg/m2 886 (24.6) 720 (24.1)
30–40 kg/m2 801 (22.3) 668 (22.3)
N40 kg/m2 226 (6.3) 179 (6.0)
Smoking history
Current 602 (16.7) 545 (18.2)
Former 636 (17.7) 527 (17.6)
Never 2359 (65.6) 1920 (64.2)
Contraceptive history
Continuous user 1570 (43.6) 1326 (44.3)
New start 619 (17.2) 515 (17.2)
Prior user 1408 (39.1) 1151 (38.5)
SD, standard deviation.
a BMI data were missing for 1 patient (b1%).
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which another contraceptive was used. Life-table analyses
estimated cumulative failure rates at the end of 1 year of
2.82% (95% CI, 2.23–3.57) for all PITT users and 3.06%
(95% CI, 2.19–4.27) for compliant users, using 28-day
cycles as the basis of the calculation intervals.able 2
regnancy rates reported as PI.
No. of
pregnancies
No. of completed 28-day
cycles
PI (95% CI)
ll use 70 30,366 3.00 (2.34–3.79)
ypical use 70 28,518 3.19 (2.49–4.03)
ompliant
use
54 27,153 2.59 (1.94–3.37)
he all-user analysis included all complete 28-day cycles; typical-use
nalysis included all complete 28-day cycles during which no other birth
ontrol method was used; and compliant-use analysis included all complete
8-day cycles during which no other birth control method was used and the
articipant was deemed to be compliant during the cycle. A participant was
onsidered noncompliant if she skipped two or more consecutive pills; had
n overall adherence of b80%, based on a combination of diary data and pill
ounts; or used a prohibited medication.3.2. Cycle control
The pattern of scheduled bleeding or spotting days was
stable across all 4 extended cycles (median of 4 days in
cycles 1, 2 and 4 and 3 days in cycle 3). Amenorrhea (no
bleeding or spotting at any time during the 91-day cycle)
occurred in approximately 1.9% of women during cycle 1,
7.7% during cycle 2, 10.7% during cycle 3 and 10.1% during
cycle 4.
The mean and median number of unscheduled bleeding or
spotting days per cycle and unscheduled bleeding days
consistently decreased from cycle 1 to cycle 4 (Fig. 3). For
example, median unscheduled bleeding days decreased from
4 (1.0 day/woman-month) in cycle 1 to 0 in cycles 2 through
4. Fewer mean and median unscheduled bleeding or spotting
days were reported with higher doses of EE (25 and 30 mcg)
later in the cycle (Fig. 4).3.3. Safety and tolerability
The types and incidence of reported AEs were consistent
with those of other ER COCs. The most common treatment-
emergent AEs (TEAEs) were headache (11.7%), nasophar-
yngitis (9.5%) and upper respiratory tract infection (9.0%)
(Table 3). The most common treatment-related AEs were
metrorrhagia (5.9%) and headache (4.5%).
The discontinuation rate over the 1-year course of
exposure was 40.4%. Thirteen percent of the study
population discontinued due to AEs, and 4.6% discontinued
due to bleeding or spotting AEs. The most commonly
reported AE leading to discontinuation was metrorrhagia
(2.9%). Fifty-eight women experienced serious AEs. Of
these events, 13 resulted in discontinuation from the trial and
7 were considered treatment related: deep vein thrombosis
(n=2), outcome of pregnancies (n=2), gallbladder problems
(n=2) and pulmonary embolism (n=1). There were no deaths
in this trial. No unexpected changes in vital signs and
laboratory test results for chemistry, lipids, hematology and
urinalysis were noted over the course of the study.4. Discussion
In this 1-year trial, the novel ADER demonstrated
efficacy for the prevention of pregnancy comparable with
that seen with other ER COCs [8,10,24,25]. Typical-use and
compliant-use PIs were 3.19 and 2.59 pregnancies per 100
woman-years of use, respectively.
The life-table method confirmed the results of the PI
analysis, indicating that the cumulative failure rate was
3.06% for compliant users and 2.82% for all users. Estimates
of contraceptive failure may be slightly lower for all users
because cycles in which additional birth control methods
were used were excluded from the compliant- and typical-
user analyses. Because variations in study design can affect
PIs, comparisons of contraceptive efficacy from different
studies should be made with caution [25]. Still, results from
COC studies in recent decades suggest a trend towardT
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304 D.J. Portman et al. / Contraception 89 (2014) 299–306increasing — or creeping — PIs and life-table failure rates
over time [25,26]. Numerous factors likely contribute to this
trend, including more frequent and accurate pregnancy
testing, differences in definitions of on-treatment pregnan-
cies and lack of confirmation of COC adherence
[9,10,13,25,27]. Standardization of COC study design and
analyses are needed to facilitate study interpretation.
Although contraceptive efficacy and safety were the
primary focus of this trial, its bleeding results were consistent
with results from a phase 2 study comparing three
experimental ADERs with a conventional LNG/EE extended
regimen [21]. Bleeding patterns were similar between all of
the experimental and conventional LNG/EE regimens, so the
lowest-dose regimen was selected for further development.
Because of its ascending EE dose, ADER provides
reduced exposure to estrogen compared to 30-mcg EE ERs,
which may result in reduced estrogen-related AEs [28–30].
The AE incidences in this trial are consistent with those
observed with low-dose COCs, confirming that ADER is
safe and well tolerated [8,9].
Overall, TEAEs were few in number, unremarkable and
consistent with those seen with other COCs. The rate of
venous thromboembolism (n=3) was 11/10,000 woman-
years, in line with the incidence of VTEs in other COCclinical trials [31,32]. Of the TEAEs recorded, only headache
occurred with an incidence N10% (11.7%), a rate lower than
those observed in other studies of LNG/EE ERs (21%–33%)
[8,10].
Study limitations include its open-label design, the
absence of a comparator and lack of objective measurement
of adherence. Adherence was assessed by self-reported
participant diaries and pill counts. Studies of COC adherence
have shown a substantial discrepancy between participant
self-reporting of adherence and actual adherence as revealed
by electronic monitoring of pill packages [33] and
pharmacokinetic assessments of contraceptive steroids
analyzed in blood samples [34,35].
Nonetheless, this large clinical trial demonstrated that
ADER is effective for the prevention of pregnancy. This 91-
day ER results in four scheduledwithdrawal bleeding episodes
each year with a low and decreasing incidence of unscheduledF
s
N
h
d
Table 3
Safety and tolerability: TEAEs
AE No. (%) (N=3597)
Headache 420 (11.7)
Nasopharyngitis 342 (9.5)
Upper respiratory tract infection 323 (9.0)
Sinusitis 246 (6.8)
Nausea 241 (6.7)
Metrorrhagia 216 (6.0)
Urinary tract infection 215 (6.0)
Acne 193 (5.4)
Dysmenorrhea 188 (5.2)
Weight increase 163 (4.5)
Back pain 153 (4.3)
Vaginal bleeding 112 (3.1)
Menorrhagia 18 (0.5)
305D.J. Portman et al. / Contraception 89 (2014) 299–306bleeding/spotting after cycle 1. Moreover, ADER exposes
women annually to less estrogen than 30-mcg ERs and similar
estrogen to 21/7 regimens while minimizing unscheduled
bleeding. ADER, a novel LNG/EE ER in which EE doses
increase when unscheduled bleeding typically occurs and
includes EE 10mcg tomodify the traditional HFI, provides the
benefits of quarterly scheduled bleeding and offers a unique
approach to minimizing unscheduled bleeding.
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